Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CTXR stock price vs PANW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PANW's multiple
Needs PANW P/S.
Implied fair value · at CTXR's multiple
Needs CTXR P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · PANW FY 2025 (ended Jul 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Citius Pharmaceuticals, Inc. · implied price per share
Bear
$0.09
Base
$0.11
Bull
$0.13
PALO ALTO NETWORKS, INC · implied price per share
Bear
$15.82
Base
$18.61
Bull
$21.40
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.01x
0.25x
Net debt / EBITDA
Leverage against operating earnings
0.09x
-0.47x
Cash and equivalents
Liquid reserves on the balance sheet
$4.25M
$2.90B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
CrowdStrike Holdings, Inc.
CTXR vs CRWD
Zscaler, Inc.
CTXR vs ZS
Okta, Inc.
CTXR vs OKTA
CHECK POINT SOFTWARE TECHNOLOGIES LTD
CTXR vs CHKP
Rapid7, Inc.
CTXR vs RPD
Cisco Systems, Inc.
CTXR vs CSCO
$1.00M
$1.99B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CTXR can materially improve revenue, margins, and financial quality from current levels, then a speculative hold may be justified; otherwise, the data supports avoiding or reducing exposure because the valuation gap is not backed by profitability, growth, or balance-sheet quality.
CTXR’s current price of $0.57 sits well above PANW-implied price of $0.13, implying -76.8% downside versus the PANW-relative P/S framework. That said, CTXR is also inside its historical band of $0.52 to $0.63, so the stock is not obviously cheap relative to its own trading history.
Supporting Metrics
